AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31902533 — intervention group
Group type: COMPARATOR
Intervention: Veneered zirconia-based fixed partial dentures (FPDC)
Number of subjects: 82
Study 31902533 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall for crowns
Number of subjects: 82
Study 31902533 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall for fixed partial dentures (FPDs)
Number of subjects: 82
Study 31902533 — intervention group
Group type: COMPARATOR
Intervention: Technical complications in zirconia FPDs
Number of subjects: 82
Study 31902533 — intervention group
Group type: COMPARATOR
Intervention: Technical complications in metal-ceramic FPDs
Number of subjects: 82
Study 31902533 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological complications for crowns
Number of subjects: 82
Study 31902533 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological complications for FPDs
Number of subjects: 82
Study 31902533 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 82
Study 31902533 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal conditions
Number of subjects: 82
Study 31064365 — intervention group
Group type: EXPERIMENTAL
Intervention: COSMOS intervention (educational programs, training in clinical evaluation, interprofessional medication review with collegial mentoring)
Number of subjects: 297
Study 28914503 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel (testosterone replacement therapy, n = 20)
Number of subjects: 39
Study 28914503 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 19)
Number of subjects: 39
Study 26498404 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary lifestyle intervention
Number of subjects: 377
Study 26498404 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 377
Study 23838242 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglactin 910 (PGI)
Number of subjects: 40
Study 23838242 — intervention group
Group type: COMPARATOR
Intervention: Polyglactin 910 (PGS)
Number of subjects: 40
Study 21514125 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum extract STW 3-VI
Number of subjects: 154
Study 21514125 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg)
Number of subjects: 154
Study 21514125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 18583430 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 20
Study 18583430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17515584 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid (various formats: decision board, decision booklet with audiotape, interactive computer program)
Number of subjects: 98
Study 17515584 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid (various formats)
Number of subjects: 98
Study 17515584 — intervention group
Group type: EXPERIMENTAL
Intervention: Unblinding of treatment name
Number of subjects: 98
Study 14734060 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal nerve transfer
Number of subjects: 36
Study 14734060 — intervention group
Group type: COMPARATOR
Intervention: Phrenic nerve transfer
Number of subjects: 36
Study 12269863 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 5mg or 10mg
Number of subjects: 0
Study 12269863 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 10mg
Number of subjects: 0
Study 12269863 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan
Number of subjects: 0
Study 12269863 — intervention group
Group type: COMPARATOR
Intervention: Rizatriptan, zolmitriptan, naratriptan
Number of subjects: 0
Study 9821034 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 1142
Study 9821034 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment alone
Number of subjects: 1142
Study 7651068 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin 4 mg/kg by infusion over 30 minutes once daily (Single-Dose Group, SG) (N = 25)
Number of subjects: 54
Study 7651068 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin 2 mg/kg intravenously twice daily (Double-Dose Group, DG) (N = 29)
Number of subjects: 54
Study 2569321 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 0
Study 2569321 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 0
Study 2569321 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipivefrin
Number of subjects: 0
Study 2569321 — intervention group
Group type: COMPARATOR
Intervention: Adrenaline
Number of subjects: 0
Study 2569321 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol with Dipivefrin
Number of subjects: 0
Study 16791 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketazolam (15 mg capsules, flexible dosage range of 15-75 mg, average optimum therapeutic dose of 46.9 mg once daily at bedtime)
Number of subjects: 79
Study 16791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 16791 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketazolam
Number of subjects: 79
Study 16791 — intervention group
Group type: COMPARATOR
Intervention: Ketazolam and Placebo
Number of subjects: 79
Study 31607278 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial record charts for self-recording dietary diversity
Number of subjects: 113
Study 31607278 — intervention group
Group type: COMPARATOR
Intervention: Household 24-hour food recall (H24HR)
Number of subjects: 113
Study 29026141 — intervention group
Group type: EXPERIMENTAL
Intervention: IM + EP
Number of subjects: 0
Study 29026141 — intervention group
Group type: EXPERIMENTAL
Intervention: ID + IM (without EP)
Number of subjects: 0
Study 29026141 — intervention group
Group type: EXPERIMENTAL
Intervention: TC + IM (without EP)
Number of subjects: 0
Study 26590478 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (1-Hz) combined with NRT (21-mg patch) for 2 weeks
Number of subjects: 37
Study 26590478 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS combined with NRT (21-mg patch) for 2 weeks
Number of subjects: 37
Study 26590478 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 37
Study 26590478 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 37
Study 23900662 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead-time TTO
Number of subjects: 387
Study 23900662 — intervention group
Group type: EXPERIMENTAL
Intervention: Lag-time TTO
Number of subjects: 387
Study 23900662 — intervention group
Group type: EXPERIMENTAL
Intervention: Both variants
Number of subjects: 387
Study 20642485 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy (4 to 7 mL of oxygen ozone mixture)
Number of subjects: 91
Study 20642485 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone-PIRFT (combined oxygen-ozone therapy with radiofrequency lesioning at 80°C for 360 s)
Number of subjects: 91
Study 20642485 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone-PIRFT
Number of subjects: 91
Study 18799338 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (0.075 IU kg(‐1)day(‐1))
Number of subjects: 7
Study 18799338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 18799338 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH
Number of subjects: 7
Study 17893293 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen 0.625 mg/medroxyprogesterone acetate 2.5 mg for 4 months
Number of subjects: 180
Study 17893293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 15227726 — intervention group
Group type: EXPERIMENTAL
Intervention: Roy-Camille method
Number of subjects: 40
Study 15227726 — intervention group
Group type: EXPERIMENTAL
Intervention: Magerl method
Number of subjects: 40
Study 15227726 — intervention group
Group type: EXPERIMENTAL
Intervention: Magerl method with reduced lateral angle
Number of subjects: 40
Study 11444887 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional needle placement and manipulation
Number of subjects: 67
Study 11444887 — intervention group
Group type: COMPARATOR
Intervention: Needles placed away from classic positions and not manipulated (Control)
Number of subjects: 67
Study 9877000 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide 2 mg as tablet
Number of subjects: 36
Study 9877000 — intervention group
Group type: COMPARATOR
Intervention: Repaglinide 2 mg as oral solution
Number of subjects: 36
Study 9877000 — intervention group
Group type: COMPARATOR
Intervention: Repaglinide 2 mg as intravenous infusion
Number of subjects: 36
Study 7975854 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (rapid schedule: vaccination at 0, 1, 2 and 12 months)
Number of subjects: 115
Study 7975854 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (standard schedule: vaccination at 0, 1, and 6 months)
Number of subjects: 115
Study 7975854 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccine (rapid schedule)
Number of subjects: 115
Study 7975854 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccine (standard schedule)
Number of subjects: 115
Study 2522385 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 10
Study 2522385 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol
Number of subjects: 10
Study 2522385 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide and metaproterenol together
Number of subjects: 10
Study 2522385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31181728 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational winter exercise (10-day winter sports program)
Number of subjects: 0
Study 28207536 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 356
Study 28207536 — intervention group
Group type: COMPARATOR
Intervention: Cervical Plexus Anesthesia (CPA)
Number of subjects: 356
Study 27547757 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane anaesthesia (1 MAC) + propofol infusion (2-3 mg/kg/h)
Number of subjects: 50
Study 27547757 — intervention group
Group type: COMPARATOR
Intervention: Propofol infusion (5-6 mg/kg/h)
Number of subjects: 50
Study 25112085 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (Hegu (LI 4), Taichong (LR 3), Quchi (LI 11), Xingjian (LR 2))
Number of subjects: 60
Study 25112085 — intervention group
Group type: COMPARATOR
Intervention: Captopril (25 mg, three times per day)
Number of subjects: 60
Study 22090163 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F‐NaF
Number of subjects: 121
Study 22090163 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F‐FDG
Number of subjects: 121
Study 22090163 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F‐NaF and 18F‐FDG
Number of subjects: 121
Study 19616802 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation
Number of subjects: 100
Study 17505263 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon alpha-2b (9,000,000,000 IU weekly administered twice daily) and coenzyme Q10 (400 mg/day)
Number of subjects: 0
Study 17505263 — intervention group
Group type: COMPARATOR
Intervention: Recombinant interferon alpha-2b (9,000,000,000 IU weekly administered twice daily)
Number of subjects: 0
Study 15344209 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 core biopsy
Number of subjects: 240
Study 15344209 — intervention group
Group type: COMPARATOR
Intervention: 6 core biopsy
Number of subjects: 240
Study 11162337 — intervention group
Group type: EXPERIMENTAL
Intervention: Community action program
Number of subjects: 20
Study 11162337 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 20
Study 9836549 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (3 or 10 g daily for 5 weeks)
Number of subjects: 9
Study 9836549 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with stress incontinence, n=18)
Number of subjects: 9
Study 7905719 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol (2 x 80 mg/day)
Number of subjects: 10
Study 7905719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7905719 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall HRV
Number of subjects: 10
Study 2659716 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 0
Study 2659716 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium hydroxide
Number of subjects: 0
Study 2659716 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31904403 — intervention group
Group type: EXPERIMENTAL
Intervention: Images of neglect (n = 25)
Number of subjects: 74
Study 31904403 — intervention group
Group type: EXPERIMENTAL
Intervention: Images of violence (n = 25)
Number of subjects: 74
Study 31904403 — intervention group
Group type: COMPARATOR
Intervention: Control images (n = 24)
Number of subjects: 74
Study 31111580 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dual therapy without bismuth (esomeprazole 40 mg twice a day plus amoxicillin 1 g three times a day)
Number of subjects: 160
Study 28124382 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 14
Study 28124382 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed (Cycling plus Foam rolling)
Number of subjects: 14
Study 28124382 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam rolling
Number of subjects: 14
Study 28124382 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 14
Study 24621858 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (i.m.) administration of DNA vaccine (4 mg) and rAd5 (1010 PU)
Number of subjects: 60
Study 24621858 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.c.) administration of DNA vaccine (4 mg) and rAd5 (1010 PU)
Number of subjects: 60
Study 24621858 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (i.d.) administration of DNA vaccine (0.4 mg) and rAd5 (1010 PU)
Number of subjects: 60
Study 23363065 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 125 mg twice a day for 4 weeks
Number of subjects: 11
Study 23363065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 23363065 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 11
Study 23363065 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 125 mg
Number of subjects: 11
Study 21039220 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 doses of twice-yearly, increased-dose albendazole-ivermectin therapy (800 mg and 400 μg/kg; n = 25)
Number of subjects: 51
Study 21039220 — intervention group
Group type: COMPARATOR
Intervention: 2 doses of annual, standard-dose albendazole-ivermectin therapy (400 mg and 150 μg/kg; n = 26)
Number of subjects: 51
Study 21039220 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (high-dose and standard-dose)
Number of subjects: 51
Study 19043154 — intervention group
Group type: EXPERIMENTAL
Intervention: CD-ROM without support for 3 months
Number of subjects: 97
Study 19043154 — intervention group
Group type: COMPARATOR
Intervention: Waiting list followed by 15 sessions of therapist cognitive-behavioural therapy (CBT)
Number of subjects: 97
Study 15963389 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin with provisional GP IIb/IIIa inhibitors
Number of subjects: 1624
Study 15963389 — intervention group
Group type: COMPARATOR
Intervention: Routine GP IIb/IIIa inhibition
Number of subjects: 1624
Study 12823329 — intervention group
Group type: COMPARATOR
Intervention: No direct intervention during the 12-month monitoring period
Number of subjects: 69
Study 10789668 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg/d for up to 21 days
Number of subjects: 234
Study 10789668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 8842277 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefonicid prophylaxis (1 g intravenously) 1 hour before the procedure
Number of subjects: 164
Study 8842277 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 164
Study 8341512 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser trabeculoplasty (DLT)
Number of subjects: 25
Study 8341512 — intervention group
Group type: COMPARATOR
Intervention: Argon laser trabeculoplasty (ALT)
Number of subjects: 25
Study 3538985 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 0
Study 3538985 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham TENS
Number of subjects: 0
Study 3538985 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 31736342 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 13195
Study 31736342 — intervention group
Group type: COMPARATOR
Intervention: Renin-angiotensin-aldosterone-system inhibitor
Number of subjects: 13195
Study 30522438 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressively autonomous physical activity (PAPA) program
Number of subjects: 50
Study 30522438 — intervention group
Group type: COMPARATOR
Intervention: Standard supervised physical activity (SPA) program
Number of subjects: 50
Study 24267148 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron
Number of subjects: 30
Study 24267148 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 30
Study 23161038 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (2 g tid or 4 g tid)
Number of subjects: 54
Study 23161038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 20123315 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolofylline 30 mg intravenously daily for 3 days
Number of subjects: 0
Study 20123315 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study 18308809 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ATD
Number of subjects: 18
Study 18308809 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ATD
Number of subjects: 18
Study 16610475 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia stories about American deaf celebrities
Number of subjects: 0
Study 12036724 — intervention group
Group type: EXPERIMENTAL
Intervention: HPMC capsules (oral administration)
Number of subjects: 16
Study 12036724 — intervention group
Group type: EXPERIMENTAL
Intervention: HPMC capsules (rectal administration)
Number of subjects: 16
Study 12036724 — intervention group
Group type: COMPARATOR
Intervention: Gelatine capsules (oral administration)
Number of subjects: 16
Study 12036724 — intervention group
Group type: COMPARATOR
Intervention: Gelatine capsules (rectal administration)
Number of subjects: 16
Study 12036724 — intervention group
Group type: EXPERIMENTAL
Intervention: HPMC capsules (various viscosity grades)
Number of subjects: 16
Study 10520777 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (lepirudin, i.v. bolus of 0.2 mg/kg, followed by s.c. injections of 0.5 mg/kg b.i.d. for 5 to 7 days)
Number of subjects: 1208
Study 10520777 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (lepirudin)
Number of subjects: 1208
Study 10520777 — intervention group
Group type: COMPARATOR
Intervention: Heparin (i.v. placebo bolus, followed by s.c. injections of 12,500 IU b.i.d. for 5 to 7 days)
Number of subjects: 1208
Study 10520777 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 1208
Study 7872337 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ofloxacin 400 mg immediately and twice daily thereafter (outpatient management)
Number of subjects: 182
Study 7872337 — intervention group
Group type: COMPARATOR
Intervention: Oral ofloxacin 400 mg immediately and twice daily thereafter (inpatient management)
Number of subjects: 182
Study 7872337 — intervention group
Group type: COMPARATOR
Intervention: Outpatient management
Number of subjects: 182
Study 7872337 — intervention group
Group type: COMPARATOR
Intervention: Inpatient management
Number of subjects: 182
Study 2779095 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg twice a day
Number of subjects: 11
Study 2779095 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil plus colestipol 10 grams twice a day
Number of subjects: 11
Study 2779095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 64482 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin testing with dialyzed Hymenoptera venoms (HDV)
Number of subjects: 0
Study 64482 — intervention group
Group type: COMPARATOR
Intervention: Skin testing with whole body diagnostic allergenic extract
Number of subjects: 0
Study 31570942 — intervention group
Group type: EXPERIMENTAL
Intervention: Diversion group (blood drawn into lithium heparin tube before blood culture bottles)
Number of subjects: 970
Study 31570942 — intervention group
Group type: COMPARATOR
Intervention: Control group (blood cultures first, then lithium heparin tube)
Number of subjects: 970
Study 31570942 — intervention group
Group type: EXPERIMENTAL
Intervention: Diversion group
Number of subjects: 970
Study 31570942 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 970
Study 31319192 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.7mcg/kg/h)
Number of subjects: 19
Study 31319192 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 19
Study 27883209 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue-to-palate resistance training (TPRT) for 4 weeks (5 days per week) plus traditional dysphagia therapy
Number of subjects: 35
Study 27883209 — intervention group
Group type: COMPARATOR
Intervention: Traditional dysphagia therapy
Number of subjects: 35
Study 27883209 — intervention group
Group type: EXPERIMENTAL
Intervention: TPRT plus traditional dysphagia therapy
Number of subjects: 35
Study 25733634 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein diets (5%, 15%, or 25%)
Number of subjects: 25
Study 25733634 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet group (excess energy from fat)
Number of subjects: 25
Study 25733634 — intervention group
Group type: EXPERIMENTAL
Intervention: All 3 groups (over 8 weeks)
Number of subjects: 25
Study 25733634 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet group
Number of subjects: 25
Study 25733634 — intervention group
Group type: EXPERIMENTAL
Intervention: Days 1, 14, and 56
Number of subjects: 25
Study 25733634 — intervention group
Group type: EXPERIMENTAL
Intervention: Excess energy as protein
Number of subjects: 25